Using a modified Repeat Expansion Detection (RED) assay, that was optimized for individual oligonucleotides, unrelated individuals were systematically screened for maximal repeat sizes of each of the ten possible trinucleotide repeats. Cloned trinucleotide repeats were generated and used as standards for the detectability of single copy trinucleotide repeat fragments. When the size distributions of trinucleotide repeats were compared to previously reported data, significant differences were found for the CTT repeat, which corresponds to the expanded GAA repeat in Friedreich ataxia, as well as for ATT, CCT and GTT repeats. Since 30-35% of normal individuals have CTG/CAG trinucleotide repeat sizes of 180 bp or more, we investigated the question whether small-scale CTG/CAG repeat expansions are detectable on a population basis by using the RED technique. We blindly screened 20 HD probands with CAG expansions of the HD gene, ranging in size between 120 and 174 bp, and found that a shift to larger CAG size ranges is clearly detectable when comparing the distribution of maximal repeat sizes in the disease group to a control group. Our study, therefore, demonstrates that the application of the RED assay to a population of probands and a population of controls allows the detection of small-scale CTG/CAG repeat expansions in the size range of the expanded HD gene and present in a single allele. We also provide standards and control data for the detection of other trinucleotide repeat expansions.
INTRODUCTION
Expansions of trinucleotide repeats can cause human genetic disorders by at least three different mechanisms. The most common one identified thus far involves CAG expansions encoding polyglutamine tracts in the coding region of a gene. This group includes five neurodegenerative disorders, spinobulbar and muscular atrophy (SBMA), Huntington disease (HD), spinocerebellar ataxia 1 and 3 (SCA1 and SCA3) and dentatorubral and pallidoluysian atrophy (DRPLA) (1) . The underlying mutational mechanism is believed to be a gain of function. Disorders of the second class are caused by trinucleotide repeat expansions (TREs) in the non-coding region of the gene (with either CTG, CGG or GAA expanded). Included are fragile X syndrome (FRAXA and FRAXE loci), myotonic dystrophy (DM), and Friedreich ataxia (FA) (2, 3) . The disease phenotypes for fragile X syndrome and FA are most likely due to loss of function. The mechanism by which the expanded trinucleotide repeat in the 3′-untranslated region of the DM-protein kinase gene causes the DM phenotype is unclear. Possibilities include a dominant-negative effect of the mutant mRNA on stability of the transcript from the normal allele (4) or disruption of other genes in the region (5) . That loss of function is not the primary mechanism is further supported by mice homozygous for targeted disruptions of the Dmpk gene. These mice have a late-onset mild disorder (6, 7) . The third class is exemplified by Jacobsen syndrome (JS), a chromosomal imbalance syndrome caused by heterozygous deletion of distal 11q. In the two known probands, the breakpoints were mapped near a fragile site, FRA11B, that was recently identified as a CCG repeat expansion within the proto-oncogene CBL2 (8) . The expansion causes a fragile site that may predispose to chromosome breakage and deletion formation, but the phenotype results from haploinsufficiency for multiple genes due to the chromosome 11q deletion. Expansions causing the fragile site alone are not associated with a known phenotype. Repeat expansions at other loci (e.g. FRAXF and FRA16A) are apparently benign (3) , thus the identification of expanded repeats may not always be clinically meaningful.
In disorders with repeat expansions in the coding region, the repeat sizes fall into defined ranges (e.g. 105-363 bp in HD probands), whereas in disorders with repeat expansions in the non-coding region (>600 bp in fragile X, >225 bp in DM and 600-2700 bp in FA), the repeats are usually larger and their exact size is not always known (3, 9) . The phenomenon of anticipation has been observed in all dominant TRE disorders, but not for FA that is recessively inherited (2) .
A recently described technique called Repeat Expansion Detection (RED) allows a genome-wide search for TREs (10, 11) . In a two-step cycling process using a large number of denaturation and annealing plus ligation cycles and a high concentration of target DNA, single stranded multimers of a triplet repeat oligonucleotide are produced by a thermostable ligase. The multimers, detected by hybridization to a complementary oligonucleotide, vary in length with the largest fragment reflecting the length of the largest repeat in the target DNA. Although the RED assay has already been applied to search for CAG expansions in common neuropsychiatric disorders with anticipation (12) (13) (14) (15) , little effort has been undertaken to assess the sensitivity of the method. For TREs other than CAG, CTG, CGG and GAA, where positive controls are available through probands, no positive controls have been experimentally generated and applied to RED assays of human populations.
Our work addresses two concerns about the sensitivity of the RED assay. First, TREs of single-copy genes might be missed due to the low amount of target DNA they provide in a given amount of genomic DNA. Second, such TREs might be masked by the background of larger repeat sizes at multiple dispersed loci that are present in the normal population and are not associated with disease. For example, FISH analysis has revealed multiple chromosomal locations to which biotinylated CCA and AGG polymers hybridize (16) . Since 30% of 274 normal individuals screened for CTG expansions by RED had maximal repeat sizes of 180 bp and greater (13) , TREs within the size ranges found in SBMA (120-186 bp), DRPLA (162-210 bp), SCA1 (123-243 bp), SCA3 (204-237 bp) or HD (105-363 bp) (9) could potentially be missed by this screening method.
By using a modified RED assay which we optimized for each specific oligonucleotide, we studied up to 92 unrelated individuals for expansions of the ten possible trinucleotide repeats. For positive controls, we generated cloned trinucleotide multimers and/or used genomic DNA of probands with DM. The sensitivity of the RED assay for detection of all ten possible trinucleotide repeats was evaluated by determining the smallest detectable amount for each cloned target repeat. For some trinucleotide repeats, the frequencies of distinct size classes in the population were found to be significantly different from previously published data. Furthermore, the RED assay was able to detect small-scale TREs in a group of 20 HD probands when compared to a group of 19 controls, despite a background of larger trinucleotide repeats that were present in some individuals from both groups.
RESULTS

Sensitivity of the RED assay
Detection of a TRE in one allele of a single copy gene. The limits of TRE detection by the RED method were systematically determined by dilution experiments of synthesized and cloned triplet repeat multimers. Plasmid DNA with a 189 bp CAG repeat (HD-CV6) was mixed with 0.5 µg of genomic DNA and used as template in a RED assay with the (CTG) 10 oligonucleotide (Fig. 1) . In a dilution series of 10 ng, 1 ng, 100 pg, 10 pg, 5 pg, 1 pg and 100 fg, the cloned repeat was detected at 5 pg in its correct size (Fig. 1, lane 4) . At 1 pg of plasmid DNA, the largest multimers were 90 bp in size, at 100 fg, no multimers were detectable (not shown). At higher concentrations of 1 ng and 100 pg of plasmid DNA, an additional multimer larger than the cloned control oligonucleotide appeared (Fig. 1, lanes 1 and 2) . The increase of genomic carrier DNA to 10 µg did not decrease the sensitivity of the reaction, i.e. no significant competition occurred between the templates derived from genomic DNA and the cloned CAG repeat (HD-CV6) (data not shown). For the other trinucleotide repeats, non-linearized and linearized cloned repeat multimers were used as templates to test the sensitivity of the reactions. In general, the sensitivity was increased by linearization of the plasmids containing the repeat multimers.
The CAG repeat in plasmid HD-CV6 was detected in its correct size at an amount of 5 pg of linearized DNA that contains 0.3 pg of the cloned repeat. From these data we can estimate how much total human genomic DNA will have to be used for detection of a 189 bp single copy fragment. As the diploid human genome contains ∼6 × 10 9 bp, 0.3 pg of a 189 bp DNA fragment would be represented in ∼10 µg of total human genomic DNA. Therefore, our RED assay would require ∼10 µg of template DNA for the detection of a 189 bp CAG repeat in a single allele. The nine other cloned trinucleotide repeats, ranging in size between 54 bp (ATT) and 243 bp (ATG), were also linearized and tested in dilution series of 100 pg, 10 pg and 5 pg. All of them were detectable at 5 pg of plasmid DNA (data not shown).
Lymphoblastoid cell line DNA from three probands with myotonic dystrophy (DM) was tested with a (CTG) 10 oligonucleotide (Fig. 1, lanes 5-7) . For sample GM03756 with a repeat of <1.5 kb, CTG multimers of up to 330 bp were produced (lane 5), for GM03990A with a repeat size of 150-240 bp, a multimer of 240 bp was produced (lane 6), and for GM03696B with a TRE of 1.5-3.0 kb, CTG multimers of 390 bp, close to the upper limit of resolution of the polyacrylamide gel, were detected upon longer exposure (lane 7). A similar upper limit of resolution (357 bp of a CTG repeat) was reported by others (16) .
Detection of the expanded HD gene
In a blinded study, DNA of 20 probands diagnosed with HD was compared with DNA of 19 controls in a RED assay with the (CTG) 10 oligonucleotide. Control and probands' reactions were loaded alternately on two gels. The size of the expanded HD gene of each proband had been previously determined for DNA diagnostic purposes and was disclosed after three of the authors had independently scored the size of the largest multimer for each proband and control. In none of the 20 samples was the CTG repeat size, as determined by RED, smaller than the actual repeat size of the expanded HD gene (Fig. 2a,b) . In eight cases, the sizes of the CTG multimers were almost exactly matching the sizes of the expanded HD genes (probands 1, 2, 6, 13, 15, 16, 19, 20, in Fig. 2b ). In the other 12 cases, the detected CTG multimers exceeded the sizes of the expanded HD genes. Our results obtained with the control population suggest that these differences are due to CTG/CAG repeat expansions in the genome that are unrelated to the HD locus. A total of 74 unrelated control individuals was screened with the (CTG) 10 oligonucleotide. The maximal repeat sizes ranged from 120 bp to 270 bp. The CTG/CAG repeat sizes, as determined by RED, of all unrelated non-HD and HD individuals are compared in Figure 2c . The most striking difference is the shift from the 120 bp peak to the 150 bp and 180 bp peaks for the group of HD probands, with lesser differences in the 210 bp and larger size ranges. To determine whether the observed differences in distribution patterns are statistically significant, we compared the data of the two groups, excluding HD proband 5 with a 360 bp CTG/CAG repeat known to be unrelated to the expanded HD gene. A significant difference between the two groups was found both by the Mann-Whitney test (p = 0.0074) and by the Two Sample T test (p = 0.0069).
Frequency of trinucleotide repeats at discrete lengths
The population distributions of the maximal sizes for eight of the remaining nine trinucleotide repeats are illustrated in Figure 3 , and autoradiograms for the CTT, ATG, TGG and GTT RED assays are shown in Figure 4 . When compared to reports in the literature (Table 1) , the overall sensitivity of our RED assay seemed to be similar for CTG, CGG, CGT and AGT, decreased for CCT, and increased for CTT, GTT, TGG, ATG and ATT based on the fraction of individuals with maximal repeat sizes of 180 bp and larger and on the presence of single ligation products.
The CCG repeat tested with a (CGG) 10 oligonucleotide was difficult to detect by the RED method, probably due to secondary structure formation (17) or other processes that would inhibit hybridization of the oligonucleotides. Genomic DNA of a fragile X proband that was positive for the TRE on Southern blot did not yield distinct bands but generated a strong signal throughout the lane. In contrast, distinct fragments of 60 bp could be detected in 36 unrelated individuals (Table 1 ). In 22 of them, putative larger fragments of 90 to 120 bp also appeared (data not shown). The (CTT) 12 oligonucleotide revealed large maximal repeat sizes ranging from 252 bp to 540 bp in 53 unrelated individuals. The presence of large multimers close to the upper limit of resolution of the gel was confirmed by performing RED with a (CTT) 33 oligonucleotide and by longer electrophoresis of (CTT) 12 reactions. For the (ATG) 10 oligonucleotide, the maximal repeat sizes ranged between 60 bp and 240 bp (n = 31), and the (TGG) 10 oligonucleotide detected maximal repeat sizes between 120 bp and 210 bp (n = 46). For the (GTT) 10 oligonucleotide, single ligation products of 60 bp were obtained in all cases tested (n = 54) and the maximal repeat size was 90 bp (n = 24). For the CCT repeat, 25 out of 35 unrelated individuals had a maximal repeat size of 60 bp, 10 had a maximal repeat size of 90 bp and none of them had larger repeat sizes. With the (AGT) 12 oligonucleotide, 57 unrelated individuals, with the (ATT) 12 oligonucleotide, 52 unrelated individuals, and with the (CGT) 10 oligonucleotide, 54 unrelated individuals were analyzed. Single ligation products corresponding to the maximal repeat sizes were present in 93, 85 and 89% of the cases, respectively.
DISCUSSION
While the initially described disorders caused by TREs were limited to CGG/CCG and CTG/CAG repeats, the recent discovery of an intronic GAA repeat expansion as the cause for FA shows that other TREs exist and have disease-causing potential. The search for expansions of any trinucleotide in other neurologic or neuropsychiatric disorders by use of the RED protocol requires, however, that the power and limitations of this technique be completely evaluated. In this report, we have addressed the sensitivity of the technique, both experimentally and in light of the background of polymorphic TREs in the human genome. Our method was modified from previous reports (10, 11, 16) , in particular, to improve the sensitivity for the AT-rich trinucleotide repeats. As positive controls, we used cloned multimers for all ten trinucleotide repeats, in addition to genomic DNA from probands with DM. In a dilution series of the cloned trinucleotide repeats, we defined the amount of genomic DNA required to detect the expansion of a single allele by this assay.
Our analysis of genomic DNA from 20 unrelated HD probands with expanded CAG repeats in the size range of 120 to 180 bp revealed that it is possible to detect an expansion of this size against the background of CTG/CAG repeat length polymorphisms at multiple loci. Comparison of the median repeat sizes (MannWhitney test) and the mean repeat sizes (Two-sample T-test) revealed a significant difference between HD and controls (p = 0.0074 and 0.0069, respectively). In a histogram comparing the maximal repeat sizes between the two groups, a striking shift of the maximal CTG/CAG repeat size from 120 bp towards 150 and 180 bp was present, that most likely reflects the expansion at the HD locus. The frequencies of maximal repeat sizes above 180 bp were not different between the two groups. A single 360 bp repeat expansion in the HD group was clearly unrelated to the expansion of the HD gene, known to be 126 bp in this case. In 11 other cases, the maximal repeat sizes determined by RED also exceeded the expected size due to the HD locus. In none of the HD cases, however, was the CTG repeat size, as determined by RED, smaller than the size of the expanded HD gene, giving further evidence that the assay did not miss the expansion of a single allele.
For the CTT repeat (identical to the GAA repeat expanded in FA) large maximal repeat sizes were detected in all screened individuals. In contrast to a previous report, in which only 10% of 172 screened individuals had maximal repeat sizes of 180 bp and more (18) , the frequency was 100% in our group (n = 53). Similar to our results, an investigation of trinucleotide repeats in human genomic clones with small insert sizes also found the relatively largest expansions for CTT repeats (19) . Since all the individuals we screened had CTT repeat sizes equal to or larger than 252 bp, a disease-causing CTT repeat expansion smaller than 252 bp would be impossible to detect by the RED assay and would be missed. In FA alleles, the expansions are larger than 600 bp and should be detectable.
When compared to previously reported data, the frequency of trinucleotide repeats at or above discrete lengths seemed to be similar for CTG, CGG, CGT and AGT, higher for CTT, GTT, TGG, ATG and ATT, and lower for CCT ( Table 1 ). The differences may be due in part to increased sensitivity for our RED reactions, particularly those performed with the AT-rich oligonucleotides, or to differences in size distributions of triplet repeats in different populations, e.g. among different types of Caucasians (20) . In addition, a small possibility exists that our use of relatively short oligonucleotides (30mers or 36mers) may allow the formation of single ligation products that might be missed with larger oligonucleotides (e.g. 51mers as in refs 10 and 20) . As the sizes of most oligos used in previous studies were only in the 36mer to 45mer range (18) , it is remarkable, that we detected ligation products for several trinucleotide multimers (CTT, GTT, ATT) that had not been seen before. Some of these could harbor premutations that are subject to disease-causing expansions. The new data we provide about the distribution of trinucleotide repeat sizes in the normal population may help to distinguish normal from expanded repeat sizes when studying other candidate trinucleotide repeat disorders like hereditary ataxias, epilepsy, schizophrenia and bipolar affective disorder.
With the identification of the expanded GAA repeat in FA it appears that any recessive disorder could result from such a mutational mechanism and would have to be included into the list of candidate diseases. Since we detected large CTT (=GAA) multimers in all of our screened individuals this trinucleotide repeat might be prone to expand also in other human diseases.
In published studies of other neuropsychiatric candidate disorders like schizophrenia, bipolar affective disorder and familial Parkinson's disease, the RED assay was applied almost exclusively to screen for CAG (=CTG) repeat expansions, since most of the known TRE disorders are due to expansions of this particular triplet. While no differences from controls were found in familial Parkinson's disease (12), positive results were reported for schizophrenia and bipolar affective disorder (BPAD) (13) (14) (15) . The interpretation of negative results is made difficult by the absence of positive controls, such as standard amounts of cloned trinucleotide repeats on each blot, that would prove the detectability of expansion of a single copy allele under the experimental conditions used. The positive results reported for BPAD and schizophrenia are based on statistical comparisons to control groups alone and fail to show the characteristic change in maximal size distributions that we observed in the group of 20 HD probands representing a homogeneous population with TREs at the same locus. We have shown that RED is capable of detecting even small expansions against a background of polymorphic larger repeat sizes as long as the disease population is homogeneous. In genetically heterogeneous disorders, a relatively minor contribution of a TRE at a single locus could be difficult to detect. 
MATERIALS AND METHODS
Nomenclature
A systematic nomenclature for trinucleotide repeats was proposed by Sutherland and Richards (1995) (21) . Since our oligonucleotides were synthesized according to a nomenclature used earlier in the literature (10, 18) , we refer to the ten trinucleotide repeats as listed in Table 1 (with the new nomenclature of Sutherland and Richards in parentheses). When citing the literature for trinucleotide repeat disorders, the trinucleotides are named according to the original publications. The expanded CAG repeat in HD is referred to as CTG when it was screened with a CTG oligonucleotide.
Oligonucleotides
All oligonucleotides were purified on a 12% denaturing polyacrylamide gel prior to use in the ligation reaction (22) . The (CTT) 33 oligonucleotide was synthesized with a 5′dimethoxytrityl group, enriched by Poly-Pak TM cartridges (Glen Research, Sterling, VA), gel purified and 5′ phosphorylated using dATP and polynucleotide kinase (22) . All the other oligonucleotides were 5′ phosphorylated during synthesis.
DNA samples
Control DNA was extracted by standard procedures (22) from EBV transformed lymphoblastoid cell lines from unrelated individuals including some with disorders not known to be due to TREs. They represented a mixed population of mostly Caucasians from the Western U.S. Their mean age was 25.9 years (±17.78), and the male to female ratio was 1:1.6.
The 20 probands with HD were of similar ethnic background as the controls. Their molecular diagnosis was previously established at the UCSF Molecular Diagnostics Laboratory by a PCR/Southern blotting procedure that excludes the polymorphic repeat near the critical CAG site. The specificity of the CAG repeat PCR product was detected following Southern blot hybridization to a biotinylated (CAG) 6 oligonucleotide probe and the number of repeats determined by comparison to biotinylated sized DNA standards that have been previously verified for authentic migration next to a DNA sequencing ladder.
As positive controls for the CTG RED reactions, we used a 189 bp cloned CAG repeat (plasmid HD-CV6) and genomic DNA from three cell lines of probands with myotonic dystrophy (DM) (GM03756, GM03990A and GM03696B) who had CTG repeats of <1.5 kb, 150-240 bp and of 1.5-3.0 kb, respectively. As a possible control for the CGG reaction, we attempted to use DNA from cell lines of two fragile X syndrome probands (GM06911 and GM07365). By PCR analysis GM06911 had a CGG repeat of >600 bp, and GM07365 had an expanded fragment on Southern analysis. The cell lines with GM prefixes were obtained from the Human Mutant Cell Repository at Coriell Institute for Medical Research, Camden, NJ.
To obtain positive controls for CGG and for the other eight trinucleotide repeats, we generated cloned repeat multimers by one of two methods: annealing of two complementary oligonucleotides, ligation of the annealed products, generation of blunt ends with Klenow fragment, and ligation of the products into a blunt end plasmid vector, or standard PCR on two complementary oligonucleotides without addition of template or other primers and cloning of the PCR products into a pGEM T vector (Promega). The following multimeric clones were obtained: TGG (135 bp), CGT (81 bp), CCT (78 bp), CTT (192 bp CTT + 21 bp AAG), GTT (72 bp), AGT (222 bp), ATG (243 bp), ATT (54 bp), CGG (ca. 100 bp). Except for the CGG clone, all inserts were sequenced to rule out PCR errors.
Modified RED protocol
A modified version of a recently published RED protocol (11, 16) was applied. All reactions were performed on a Perkin Elmer Model 480 thermocycler. Reactions containing 10 µg of genomic DNA and 5 pmol of phosphorylated gel-purified oligonucleotide in 14 µl of water were heat-denatured for 5 min, and placed on ice. Following the addition of 4 µl of Ampligase (5 U/ml) (Epicentre Technologies, Madison, WI) and 2 µl of supplied Ampligase buffer, the 20 µl reactions were cycled 396 times according to the following parameters. For (CTG) 10 -, (CGG) 10 -, (TGG) 10 -and (CGT) 10 -oligonucleotides: 30 s at 70_C, 10 s at 95_C. For (CCT) 10 -, (CTT) 12 -, (GTT) 10 -, (AGT) 12 -and (ATG) 10 -oligonucleotides: 30 s at 60_C, 10 s at 95_C. (ATT) 12 -oligonucleotide: 30 s at 40_C, 10 s at 95_C. The reaction products were mixed with 15 µl of loading buffer (95% formamide, 20 mM EDTA, 0.05% bromphenolblue and xylenecyanol), electrophoresed on a 6% denaturing polyacrylamide gel (20 × 20 × 0.1 cm) (Biorad) and electrotransferred onto a Hybond N + membrane (Amersham) using a Hoefer Gene Sweep TE 90 blotting apparatus. The complementary oligonucleotides were 3′ end labelled with 32 P-dCTP using terminal transferase (Boehringer Mannheim) and hybridized to the membrane at 65_C for CTG, CGG, TGG and CGT, at 60_C for CCT, CTT, GTT, AGT and ATG and at 55_C for ATT. Blots were washed at room temperature or up to 5_C below hybridization temperature. The first washing was performed in 2× SSC, and the second washing in 1× SSC and 0.1% SDS for the CTG-oligonucleotide and in 0.1× SSC and 0.1% SDS for the other triplet repeat oligonucleotides. Blots were exposed to X-ray film for 1-10 days. RED assays were done at least twice for each DNA sample. The Minitab Statistical Software (Minitab Accelerated), Release 8, was used for statistical analysis of the data.
ABBREVIATIONS
DRPLA, dentatorubral and pallidoluysian atrophy; EBV, Epstein Barr virus; FA, Friedreich ataxia; HD, Huntington disease; RED, repeat expansion detection; SBMA, spinobulbar and muscular atrophy; SCA1, spinocerebellar ataxia 1; SCA3, spinocerebellar ataxia 3; TRE, trinucleotide repeat expansion.
